Equities Analysts Offer Predictions for CRL Q3 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Analysts at Zacks Research lowered their Q3 2026 EPS estimates for shares of Charles River Laboratories International in a research note issued on Wednesday, August 26th. Zacks Research analyst Team now expects that the medical research company will earn $2.94 per share for the quarter, down from their prior estimate of $2.98. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $11.35 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q4 2026 earnings at $3.13 EPS, FY2026 earnings at $11.15 EPS, Q1 2027 earnings at $2.56 EPS, Q2 2027 earnings at $3.23 EPS, Q3 2027 earnings at $3.30 EPS, Q4 2027 earnings at $3.40 EPS, FY2027 earnings at $12.49 EPS, Q1 2028 earnings at $3.23 EPS and FY2028 earnings at $13.82 EPS.

Several other equities research analysts have also weighed in on CRL. Robert W. Baird set a $291.00 price objective on Charles River Laboratories International in a research note on Thursday, August 6th. Royal Bank Of Canada raised their target price on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. TD Cowen boosted their price target on Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Piper Sandler set a $300.00 price target on Charles River Laboratories International in a research report on Monday, August 10th. Finally, BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a research note on Wednesday, July 1st. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $255.65.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $295.64 on Thursday. The firm has a market capitalization of $14.11 billion, a PE ratio of -60.96, a price-to-earnings-growth ratio of 3.08 and a beta of 1.38. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. Charles River Laboratories International has a 12-month low of $144.26 and a 12-month high of $300.59. The firm has a 50-day moving average price of $241.70 and a 200 day moving average price of $195.88.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm’s revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the business earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS.

Insider Buying and Selling

In related news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This trade represents a 70.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria L. Creamer sold 4,179 shares of Charles River Laboratories International stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the completion of the transaction, the executive vice president owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. The trade was a 12.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 132,429 shares of company stock valued at $32,538,088 in the last ninety days. 1.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Continuum Advisory LLC acquired a new stake in Charles River Laboratories International in the 2nd quarter valued at about $30,000. Los Angeles Capital Management LLC bought a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $42,000. Sfam LLC bought a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $43,000. Activest Wealth Management increased its holdings in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 218 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Medigen partnership supports growth potential: Medigen has teamed up with Charles River to help advance the global development and commercialization of an enterovirus vaccine. The agreement could create additional opportunities for CRL’s research, testing, and manufacturing services. Medigen links up with Charles River in push to take enterovirus vaccine global
• Positive Sentiment: Longer-term earnings forecasts increased: Zacks Research raised its FY2026 EPS estimate to $11.15 from $10.91, FY2027 to $12.49 from $12.11, and FY2028 to $13.82 from $13.01. Estimates for Q2 2027, Q3 2027, and Q1 2028 were also increased, indicating improved expectations for earnings momentum beyond the immediate quarters.
• Neutral Sentiment: Wall Street sentiment remains a focus: A recent report reviews whether analysts are bullish or bearish on CRL, but the provided information does not identify a new consensus rating or price-target change. Is Wall Street bullish or bearish on Charles River Laboratories stock?
• Negative Sentiment: Several near-term estimates were trimmed: Zacks lowered Q3 2026 EPS to $2.94 from $2.98, Q4 2026 to $3.13 from $3.15, and Q1 2027 to $2.56 from $2.58. The Q4 2027 forecast also fell slightly to $3.40 from $3.43, suggesting some caution about near-term operating performance.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.